Cellectis

Name

Cellectis

Legal name

Cellectis S.A.

Website

https://cellectis.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Cell Therapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), CAR-T & TCR-T Therapies (HLAAABAC), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• Allogeneic CAR-T therapy
• Gene editing platform
• TALEN technology
• Cell therapy manufacturing
• Adoptive immunotherapy

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Collaboration and Licensing Revenue: Revenue generated from strategic partnerships including the AstraZeneca Joint Research and Collaboration Agreement and licensing agreements with Servier/Allogene for CD19 CAR-T products. Cellectis receives development and sales milestone payments as well as royalties on net sales of licensed products.
2. Global Offering and Equity Financing: Capital raised through global offerings of ADSs on Nasdaq and ordinary shares on Euronext Paris, including exercise of underwriters' option to purchase additional shares.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Cellectis is a clinical-stage biotechnology company that develops allogeneic (off-the-shelf) CAR-T cell therapy product candidates for cancer using its proprietary TALEN® gene editing platform. Its lead candidates are lasme-cel (UCART22), a CD22-targeting therapy for relapsed/refractory B-cell acute lymphoblastic leukemia, and eti-cel (UCART20x22), a dual CD20/CD22-targeting therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The company also licenses its gene editing and manufacturing capabilities to strategic pharmaceutical partners such as AstraZeneca, Servier, and Allogene.

Product overview

Cellectis is a clinical-stage biotechnology company that has developed a portfolio of allogeneic CAR-T cell therapy product candidates enabled by its proprietary gene editing platform. The core products include lasme-cel (UCART22), a CD22-targeting allogeneic CAR-T for relapsed/refractory B-cell acute lymphoblastic leukemia currently in pivotal Phase 2 trials, and eti-cel (UCART20x22), a dual CD20/CD22 targeting allogeneic CAR-T for relapsed/refractory non-Hodgkin lymphoma in Phase 1. The technology portfolio encompasses TALEN® gene editing, TALE-based epigenetic editing (TALEM), TALE base editors (TALEB), and CssDNA non-viral gene editing processes, all powered by proprietary PulseAgile electroporation technology. The company operates end-to-end in-house GMP manufacturing facilities across three locations. Cema-cel (derived from UCART19 licensed to Servier/Allogene) represents a partnered anti-CD19 CAR-T product.

Differentiator

Problem solved

Functional benefit

Brands

• TALEN: Cellectis's flagship gene editing technology for creating CAR T therapies
• UCART
• lasme-cel
• eti-cel
• PulseAgile

Products and services

• Lasme-cel (UCART22) CD22-targeting allogeneic CAR-T cell therapy product candidate for treating relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in transplant-ineligible patients in the third line or beyond (3L+). Uses TALEN gene editing to create off-the-shelf universal CAR-T cells from healthy donor T-cells. FDA RMAT designated.
• Eti-cel (UCART20x22) Dual-targeting allogeneic CAR-T cell therapy product candidate simultaneously targeting CD20 and CD22 antigens for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r NHL) in patients who have failed at least two prior lines of therapy including CD19 CAR-T. The first allogeneic dual CAR-T targeting both CD20 and CD22 antigens.
• TALEN Gene Editing Technology Proprietary Transcription Activator-Like Effector Nuclease (TALEN) gene editing technology enabling precise DNA modifications in T-cells. Used to engineer allogeneic CAR-T therapies and licensed to pharmaceutical partners including AstraZeneca, Servier, and Allogene for co-development of cell and gene therapy products.
• PulseAgile Electroporation Technology Proprietary electroporation technology using precise electrical pulses to create temporary pores in CAR T-cells, allowing TALEN enzymes to enter and make precise gene edits without harming T-cells during processing.

Quantifiable outcome

• 100% overall response rate (ORR) in lasme-cel target Phase 2 population (n=7)
• +7 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• AstraZenecaflagshipStrategic or Co-development Partner · 1 June 2023Joint Research and Collaboration Agreement leveraging Cellectis' gene editing expertise and manufacturing capabilities to develop up to 10 novel cell and gene therapy products for areas of high unmet medical need, including oncology, immunology and rare genetic disorders. Activities are progressing under this collaboration with three programs initiated.
• ServiercoreStrategic or Co-development PartnerLicense, Development and Commercialization Agreement (signed March 6, 2019) for anti-CD19 allogeneic CAR-T products. Servier sublicensed rights to Allogene for certain territories. Cellectis eligible for up to $340 million in development and sales milestones plus low double-digit royalties on net sales of licensed CD19 products including cema-cel. In December 2025, arbitration ruled on partial termination for UCART19 V1 (ALLO-501).
• Allogene TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerSublicensee of Servier for anti-CD19 CAR-T products (cema-cel) derived from Cellectis' UCART19 platform. Allogene is conducting the pivotal ALPHA3 trial for cema-cel in first-line consolidation for LBCL. In December 2025, Allogene won arbitration securing full development and commercial control of cema-cel in US, EU, and UK.
• Primera (inferred from partnership mention)minorOthersListed as global strategic partner in Cellectis' intellectual property section.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Allogene Therapeutics: Allogene is the closest direct peer, developing allogeneic CAR-T therapies including cema-cel derived from Cellectis' UCART19 platform licensed via Servier. It competes head-to-head in the allogeneic CAR-T space with overlapping CD19 and CD20/CD22 programs and shared scientific lineage.
• CRISPR Therapeutics: CRISPR Therapeutics develops gene-edited allogeneic CAR-T therapies (e.g., CTX112, CTX131) using CRISPR/Cas9, directly competing with Cellectis in the allogeneic CAR-T space and sharing the same target indications in B-cell malignancies.
• Fate Therapeutics: Fate Therapeutics develops off-the-shelf iPSC-derived cell therapies including CAR-T candidates, directly competing in the allogeneic/multiplexed-engineered cell therapy category with similar B-cell malignancy targets and platform-based differentiation.
• Caribou Biosciences: Caribou Biosciences develops allogeneic CAR-T cell therapies (e.g., CB-010, CB-012) using CRISPR-based gene editing, directly competing in the allogeneic CAR-T space with similar oncology indications and platform-driven differentiation.
• Precision BioSciences: Precision BioSciences develops allogeneic CAR-T therapies using its ARCUS gene editing platform, a direct competitor to Cellectis' TALEN platform in the off-the-shelf CAR-T category with comparable B-cell malignancy programs.

Broad incumbents

• Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, a broader cell therapy peer with overlapping platform engineering expertise and clinical-stage oncology pipeline though focused on TCR rather than CAR-T.
• Iovance Biotherapeutics: Iovance is a commercial-stage cell therapy company focused on tumor-infiltrating lymphocyte (TIL) therapies, a Cellectis collaboration partner (IOV-4001 PD-1 inactivated TIL) operating in the broader engineered cell therapy space.
• Bristol Myers Squibb: BMS markets Breyanzi and Abecma, leading autologous CAR-T therapies in B-cell malignancies, representing the incumbent standard of care that Cellectis' allogeneic products must displace or complement.
• Gilead Sciences (Kite): Gilead's Kite Pharma subsidiary markets Yescarta and Tecartus, the dominant autologous CAR-T franchises in lymphoma and ALL, representing the primary competitive incumbent Cellectis aims to disrupt with off-the-shelf alternatives.

Emerging players

• Beam Therapeutics: Beam Therapeutics develops base editing therapies with overlap to Cellectis' TALEB base editor platform, representing a peer in next-generation gene editing though focused on in vivo applications rather than ex vivo CAR-T.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/cellectis
• Facebookfacebook.com/cellectis
• LinkedInlinkedin.com/company/cellectis

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellectis